angioplasty

4 stories · following the connections

Business

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee

By Nasdaq OMXNov 10, 2016, 1:00 PM UTC

Business

Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference

By Nasdaq OMXOct 25, 2016, 12:02 PM UTC

Business

Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference

By Nasdaq OMXOct 25, 2016, 12:02 PM UTC

Business

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

By Nasdaq OMXApr 13, 2016, 12:00 PM UTC